[
  {
    "account_name": "AstraZeneca",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 22.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of AZD0120 in Autoimmune Diseases | trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subje | sec_filing: 6-K filed 2026-02-10 \u2013 FINAL RESULTS",
    "best_fit_trial_title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04257578",
    "best_urgency_trial_title": "A Study of AZD0120 in Autoimmune Diseases",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07295847",
    "sec": {
      "recent_total": 5,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "AstraZeneca",
    "total_score": 22.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07295847",
      "https://clinicaltrials.gov/study/NCT06542250",
      "https://www.sec.gov/Archives/edgar/data/901832/000165495426001073/a3234s.htm",
      "https://clinicaltrials.gov/study/NCT06897930",
      "https://clinicaltrials.gov/study/NCT07391657",
      "https://clinicaltrials.gov/study/NCT06564038",
      "https://clinicaltrials.gov/study/NCT07224373",
      "https://clinicaltrials.gov/study/NCT05877599"
    ],
    "score_details": {
      "trial_count": 20,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 1
  },
  {
    "account_name": "Pfizer",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "molecule match: elranatamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients  | trial_candidate: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) | trial_candidate: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With D",
    "best_fit_trial_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06215118",
    "best_urgency_trial_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06215118",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Pfizer",
    "total_score": 20.1,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06215118",
      "https://clinicaltrials.gov/study/NCT05748171",
      "https://clinicaltrials.gov/study/NCT05623020",
      "https://clinicaltrials.gov/study/NCT06152575",
      "https://clinicaltrials.gov/study/NCT05020236",
      "https://clinicaltrials.gov/study/NCT06057402",
      "https://clinicaltrials.gov/study/NCT05675449",
      "https://clinicaltrials.gov/study/NCT06974786"
    ],
    "score_details": {
      "trial_count": 14,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 2
  },
  {
    "account_name": "Allogene Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in A | trial_candidate: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | trial_candidate: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "best_fit_trial_title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07085104",
    "best_urgency_trial_title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07085104",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Allogene Therapeutics",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07085104",
      "https://clinicaltrials.gov/study/NCT06500273",
      "https://clinicaltrials.gov/study/NCT04696731",
      "https://clinicaltrials.gov/study/NCT04416984",
      "https://clinicaltrials.gov/study/NCT04093596"
    ],
    "score_details": {
      "trial_count": 5,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 3
  },
  {
    "account_name": "Kite, A Gilead Company",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | trial_candidate: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | trial_collaborator: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
    "best_fit_trial_title": "Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07375628",
    "best_urgency_trial_title": "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05396885",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Kite, A Gilead Company",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05396885",
      "https://clinicaltrials.gov/study/NCT04155749",
      "https://clinicaltrials.gov/study/NCT06144606",
      "https://clinicaltrials.gov/study/NCT06539338",
      "https://clinicaltrials.gov/study/NCT07375628",
      "https://clinicaltrials.gov/study/NCT06413498",
      "https://clinicaltrials.gov/study/NCT07304154",
      "https://clinicaltrials.gov/study/NCT06079164"
    ],
    "score_details": {
      "trial_count": 20,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 4
  },
  {
    "account_name": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap | trial_candidate: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With R | trial_candidate: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With",
    "best_fit_trial_title": "Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06297226",
    "best_urgency_trial_title": "A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06220201",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06220201",
      "https://clinicaltrials.gov/study/NCT06615479",
      "https://clinicaltrials.gov/study/NCT06297226",
      "https://clinicaltrials.gov/study/NCT07015983",
      "https://clinicaltrials.gov/study/NCT07335562",
      "https://clinicaltrials.gov/study/NCT07115745",
      "https://clinicaltrials.gov/study/NCT05869955",
      "https://clinicaltrials.gov/study/NCT06121843"
    ],
    "score_details": {
      "trial_count": 12,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 5
  },
  {
    "account_name": "Chongqing Precision Biotech Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of CD19 CAR-T Therapy for Refractory SLE | trial_collaborator: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus | trial_candidate: Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE",
    "best_fit_trial_title": "Study of CD19 CAR-T Therapy for Refractory SLE",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07403097",
    "best_urgency_trial_title": "Study of CD19 CAR-T Therapy for Refractory SLE",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07403097",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Chongqing Precision Biotech Co., Ltd",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07403097",
      "https://clinicaltrials.gov/study/NCT06222853",
      "https://clinicaltrials.gov/study/NCT07318259",
      "https://clinicaltrials.gov/study/NCT06821048",
      "https://clinicaltrials.gov/study/NCT07331467",
      "https://clinicaltrials.gov/study/NCT06892145",
      "https://clinicaltrials.gov/study/NCT07250386",
      "https://clinicaltrials.gov/study/NCT07247396"
    ],
    "score_details": {
      "trial_count": 36,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 6
  },
  {
    "account_name": "Nanjing Legend Biotech Co.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopath | trial_candidate: A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases | trial_candidate: A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases",
    "best_fit_trial_title": "A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06869278",
    "best_urgency_trial_title": "A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07331272",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Nanjing Legend Biotech Co.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07331272",
      "https://clinicaltrials.gov/study/NCT07095075",
      "https://clinicaltrials.gov/study/NCT07049081",
      "https://clinicaltrials.gov/study/NCT06869278",
      "https://clinicaltrials.gov/study/NCT06313957",
      "https://clinicaltrials.gov/study/NCT06653556",
      "https://clinicaltrials.gov/study/NCT06395870",
      "https://clinicaltrials.gov/study/NCT06494371"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 7
  },
  {
    "account_name": "Hebei Senlang Biotechnology Inc., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | trial_candidate: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | trial_candidate: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL",
    "best_fit_trial_title": "SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07234721",
    "best_urgency_trial_title": "Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07244380",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Hebei Senlang Biotechnology Inc., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07234721",
      "https://clinicaltrials.gov/study/NCT07244380",
      "https://clinicaltrials.gov/study/NCT07244406",
      "https://clinicaltrials.gov/study/NCT07161193",
      "https://clinicaltrials.gov/study/NCT05618041",
      "https://clinicaltrials.gov/study/NCT05388695",
      "https://clinicaltrials.gov/study/NCT06880913",
      "https://clinicaltrials.gov/study/NCT06874946"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 8
  },
  {
    "account_name": "Miltenyi Biomedicine GmbH",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblas | trial_candidate: DALY II Japan/MB-CART2019.1 for DLBCL | trial_candidate: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
    "best_fit_trial_title": "CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07361029",
    "best_urgency_trial_title": "CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07361029",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Miltenyi Biomedicine GmbH",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07361029",
      "https://clinicaltrials.gov/study/NCT07288879",
      "https://clinicaltrials.gov/study/NCT04844866",
      "https://clinicaltrials.gov/study/NCT06424340",
      "https://clinicaltrials.gov/study/NCT06508931",
      "https://clinicaltrials.gov/study/NCT06189157",
      "https://clinicaltrials.gov/study/NCT06508775",
      "https://clinicaltrials.gov/study/NCT03853616"
    ],
    "score_details": {
      "trial_count": 14,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 9
  },
  {
    "account_name": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies | trial_candidate: Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymph | trial_candidate: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
    "best_fit_trial_title": "Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "NA",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06871644",
    "best_urgency_trial_title": "PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07188610",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07338604",
      "https://clinicaltrials.gov/study/NCT07312630",
      "https://clinicaltrials.gov/study/NCT07188610",
      "https://clinicaltrials.gov/study/NCT06092047",
      "https://clinicaltrials.gov/study/NCT06871644",
      "https://clinicaltrials.gov/study/NCT06417398",
      "https://clinicaltrials.gov/study/NCT06361745",
      "https://clinicaltrials.gov/study/NCT06279026"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 10
  },
  {
    "account_name": "Bioray Laboratories",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Universal CAR-T Cell Therapy for MM | trial_candidate: The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | trial_candidate: Universal CAR-T Cell Therapy for NHL",
    "best_fit_trial_title": "Universal CAR-T Cell Therapy for MM",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "NA",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07248176",
    "best_urgency_trial_title": "The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05741359",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bioray Laboratories",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07248176",
      "https://clinicaltrials.gov/study/NCT05741359",
      "https://clinicaltrials.gov/study/NCT07248163",
      "https://clinicaltrials.gov/study/NCT06895811",
      "https://clinicaltrials.gov/study/NCT06485232",
      "https://clinicaltrials.gov/study/NCT06633042",
      "https://clinicaltrials.gov/study/NCT06681337",
      "https://clinicaltrials.gov/study/NCT05988216"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 11
  },
  {
    "account_name": "Bristol-Myers Squibb",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis | trial_collaborator: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients  | trial_collaborator: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel",
    "best_fit_trial_title": "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04205409",
    "best_urgency_trial_title": "CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07388277",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bristol-Myers Squibb",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07388277",
      "https://clinicaltrials.gov/study/NCT06215118",
      "https://clinicaltrials.gov/study/NCT06523621",
      "https://clinicaltrials.gov/study/NCT07333261",
      "https://clinicaltrials.gov/study/NCT04205409",
      "https://clinicaltrials.gov/study/NCT06209619",
      "https://clinicaltrials.gov/study/NCT05621096",
      "https://clinicaltrials.gov/study/NCT04003649"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 12
  },
  {
    "account_name": "Guangzhou Bio-gene Technology Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | trial_candidate: BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma | trial_candidate: BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors",
    "best_fit_trial_title": "Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07338357",
    "best_urgency_trial_title": "Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06118788",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Guangzhou Bio-gene Technology Co., Ltd",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07338357",
      "https://clinicaltrials.gov/study/NCT07196124",
      "https://clinicaltrials.gov/study/NCT07196111",
      "https://clinicaltrials.gov/study/NCT07195617",
      "https://clinicaltrials.gov/study/NCT07152210",
      "https://clinicaltrials.gov/study/NCT07152223",
      "https://clinicaltrials.gov/study/NCT07152236",
      "https://clinicaltrials.gov/study/NCT06118788"
    ],
    "score_details": {
      "trial_count": 15,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 13
  },
  {
    "account_name": "Nanjing IASO Biotechnology Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies | trial_candidate: UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies | trial_candidate: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)",
    "best_fit_trial_title": "Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07055724",
    "best_urgency_trial_title": "IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07309900",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Nanjing IASO Biotechnology Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07309900",
      "https://clinicaltrials.gov/study/NCT06743503",
      "https://clinicaltrials.gov/study/NCT06464991",
      "https://clinicaltrials.gov/study/NCT07055724",
      "https://clinicaltrials.gov/study/NCT05219721",
      "https://clinicaltrials.gov/study/NCT05759793",
      "https://clinicaltrials.gov/study/NCT06902844",
      "https://clinicaltrials.gov/study/NCT04561557"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 14
  },
  {
    "account_name": "Novartis",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL | trial_collaborator: Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma | trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_title": "Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07250087",
    "best_urgency_trial_title": "Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07250087",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Novartis",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07250087",
      "https://clinicaltrials.gov/study/NCT03549442",
      "https://clinicaltrials.gov/study/NCT04328298",
      "https://clinicaltrials.gov/study/NCT04234061"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 15
  },
  {
    "account_name": "Bellicum Pharmaceuticals",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | trial_collaborator: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | trial_collaborator: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refract",
    "best_fit_trial_title": "Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05620342",
    "best_urgency_trial_title": "Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06096038",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bellicum Pharmaceuticals",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05620342",
      "https://clinicaltrials.gov/study/NCT06096038",
      "https://clinicaltrials.gov/study/NCT03016377",
      "https://clinicaltrials.gov/study/NCT02414269",
      "https://clinicaltrials.gov/study/NCT03721068"
    ],
    "score_details": {
      "trial_count": 5,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 16
  },
  {
    "account_name": "Beijing Immunochina Medical Science & Technology Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric  | trial_candidate: Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Ery | trial_candidate: Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_title": "Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07406984",
    "best_urgency_trial_title": "Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07406984",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Beijing Immunochina Medical Science & Technology Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07406984",
      "https://clinicaltrials.gov/study/NCT06886919",
      "https://clinicaltrials.gov/study/NCT06852573",
      "https://clinicaltrials.gov/study/NCT06718738",
      "https://clinicaltrials.gov/study/NCT06690359",
      "https://clinicaltrials.gov/study/NCT06691308",
      "https://clinicaltrials.gov/study/NCT06412458",
      "https://clinicaltrials.gov/study/NCT04440436"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 17
  },
  {
    "account_name": "Nanjing Bioheng Biotech Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases | trial_collaborator: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | trial_candidate: A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.",
    "best_fit_trial_title": "Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06775912",
    "best_urgency_trial_title": "CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06622694",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Nanjing Bioheng Biotech Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06775912",
      "https://clinicaltrials.gov/study/NCT07337785",
      "https://clinicaltrials.gov/study/NCT07203404",
      "https://clinicaltrials.gov/study/NCT07142161",
      "https://clinicaltrials.gov/study/NCT06622694",
      "https://clinicaltrials.gov/study/NCT06548607",
      "https://clinicaltrials.gov/study/NCT06732492"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 18
  },
  {
    "account_name": "Novartis Pharmaceuticals",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | trial_candidate: Phase 2 Study of Rapcabtagene Autoleucel in Myositis | trial_collaborator: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lympho",
    "best_fit_trial_title": "CAR-T Long Term Follow Up (LTFU) Study",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT02445222",
    "best_urgency_trial_title": "Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06704269",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Novartis Pharmaceuticals",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06704269",
      "https://clinicaltrials.gov/study/NCT06665256",
      "https://clinicaltrials.gov/study/NCT05460533",
      "https://clinicaltrials.gov/study/NCT07048197",
      "https://clinicaltrials.gov/study/NCT06617793",
      "https://clinicaltrials.gov/study/NCT03960840",
      "https://clinicaltrials.gov/study/NCT03570892",
      "https://clinicaltrials.gov/study/NCT06785818"
    ],
    "score_details": {
      "trial_count": 15,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 19
  },
  {
    "account_name": "Genmab",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and | trial_candidate: GEN1047 for Solid Tumors - First in Human (FIH) Trial",
    "best_fit_trial_title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06458439",
    "best_urgency_trial_title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05660967",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Genmab",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05660967",
      "https://clinicaltrials.gov/study/NCT04623541",
      "https://clinicaltrials.gov/study/NCT05180474",
      "https://clinicaltrials.gov/study/NCT05852717",
      "https://clinicaltrials.gov/study/NCT06672705",
      "https://clinicaltrials.gov/study/NCT06536049",
      "https://clinicaltrials.gov/study/NCT05206357",
      "https://clinicaltrials.gov/study/NCT06458439"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 20
  },
  {
    "account_name": "Kyverna Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2,PHASE3)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | trial_candidate: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia | trial_collaborator: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple ",
    "best_fit_trial_title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2,PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06193889",
    "best_urgency_trial_title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2,PHASE3",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06193889",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Kyverna Therapeutics",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07403188",
      "https://clinicaltrials.gov/study/NCT06193889",
      "https://clinicaltrials.gov/study/NCT06451159",
      "https://clinicaltrials.gov/study/NCT06588491",
      "https://clinicaltrials.gov/study/NCT05938725",
      "https://clinicaltrials.gov/study/NCT06342960",
      "https://clinicaltrials.gov/study/NCT06400303",
      "https://clinicaltrials.gov/study/NCT06152172"
    ],
    "score_details": {
      "trial_count": 12,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 21
  },
  {
    "account_name": "Juventas Cell Therapy Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases | trial_collaborator: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma | trial_candidate: A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases",
    "best_fit_trial_title": "Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06676982",
    "best_urgency_trial_title": "Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06676982",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Juventas Cell Therapy Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07275736",
      "https://clinicaltrials.gov/study/NCT06676982",
      "https://clinicaltrials.gov/study/NCT07265206",
      "https://clinicaltrials.gov/study/NCT07091370",
      "https://clinicaltrials.gov/study/NCT05667506",
      "https://clinicaltrials.gov/study/NCT06826430",
      "https://clinicaltrials.gov/study/NCT06231368",
      "https://clinicaltrials.gov/study/NCT06316791"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 22
  },
  {
    "account_name": "Fate Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | trial_candidate: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | trial_candidate: FT819 in Subjects With B-cell Malignancies",
    "best_fit_trial_title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06241456",
    "best_urgency_trial_title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06308978",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Fate Therapeutics",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06308978",
      "https://clinicaltrials.gov/study/NCT07216105",
      "https://clinicaltrials.gov/study/NCT04629729",
      "https://clinicaltrials.gov/study/NCT06241456"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 23
  },
  {
    "account_name": "Carbiogene Therapeutics Co. Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Panc | trial_candidate: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma | trial_collaborator: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma",
    "best_fit_trial_title": "Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07394205",
    "best_urgency_trial_title": "Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06705725",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Carbiogene Therapeutics Co. Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07394205",
      "https://clinicaltrials.gov/study/NCT06705725",
      "https://clinicaltrials.gov/study/NCT06461624",
      "https://clinicaltrials.gov/study/NCT04803929"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 24
  },
  {
    "account_name": "AbbVie",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed | trial_candidate: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
    "best_fit_trial_title": "MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06414148",
    "best_urgency_trial_title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04872790",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "AbbVie",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04872790",
      "https://clinicaltrials.gov/study/NCT03933735",
      "https://clinicaltrials.gov/study/NCT05660967",
      "https://clinicaltrials.gov/study/NCT04623541",
      "https://clinicaltrials.gov/study/NCT05753501",
      "https://clinicaltrials.gov/study/NCT07097363",
      "https://clinicaltrials.gov/study/NCT07197307",
      "https://clinicaltrials.gov/study/NCT06672705"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 25
  },
  {
    "account_name": "Autolus Limited",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | trial_candidate: Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | trial_candidate: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphob",
    "best_fit_trial_title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04404660",
    "best_urgency_trial_title": "A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07400029",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Autolus Limited",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07400029",
      "https://clinicaltrials.gov/study/NCT06333483",
      "https://clinicaltrials.gov/study/NCT04404660",
      "https://clinicaltrials.gov/study/NCT07053800",
      "https://clinicaltrials.gov/study/NCT06173518"
    ],
    "score_details": {
      "trial_count": 5,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 26
  },
  {
    "account_name": "iCell Gene Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CD4CAR for CD4+ Leukemia and Lymphoma | trial_collaborator: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myel | trial_collaborator: Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia ",
    "best_fit_trial_title": "Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06071624",
    "best_urgency_trial_title": "CD4CAR for CD4+ Leukemia and Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT03829540",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "iCell Gene Therapeutics",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT03829540",
      "https://clinicaltrials.gov/study/NCT06071624",
      "https://clinicaltrials.gov/study/NCT06197672",
      "https://clinicaltrials.gov/study/NCT07328581",
      "https://clinicaltrials.gov/study/NCT04162353",
      "https://clinicaltrials.gov/study/NCT06787989"
    ],
    "score_details": {
      "trial_count": 6,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 27
  },
  {
    "account_name": "CARsgen Therapeutics Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC | trial_collaborator: A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell  | trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",
    "best_fit_trial_title": "A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07339332",
    "best_urgency_trial_title": "Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07031713",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "CARsgen Therapeutics Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07355972",
      "https://clinicaltrials.gov/study/NCT07339332",
      "https://clinicaltrials.gov/study/NCT07031713",
      "https://clinicaltrials.gov/study/NCT06730256",
      "https://clinicaltrials.gov/study/NCT06822881",
      "https://clinicaltrials.gov/study/NCT06988059",
      "https://clinicaltrials.gov/study/NCT07033299",
      "https://clinicaltrials.gov/study/NCT04581473"
    ],
    "score_details": {
      "trial_count": 19,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 28
  },
  {
    "account_name": "Rui Therapeutics Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of R | trial_collaborator: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm | trial_collaborator: RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies",
    "best_fit_trial_title": "An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07241468",
    "best_urgency_trial_title": "RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07105735",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Rui Therapeutics Co., Ltd",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07241468",
      "https://clinicaltrials.gov/study/NCT07246096",
      "https://clinicaltrials.gov/study/NCT07105735",
      "https://clinicaltrials.gov/study/NCT06976437",
      "https://clinicaltrials.gov/study/NCT06318533",
      "https://clinicaltrials.gov/study/NCT06613490",
      "https://clinicaltrials.gov/study/NCT06469190",
      "https://clinicaltrials.gov/study/NCT06337474"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 29
  },
  {
    "account_name": "Yake Biotechnology Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia | trial_collaborator: A Multicenter Study of CAR-T Cells in Primary Ph+All | trial_collaborator: Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia",
    "best_fit_trial_title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07370064",
    "best_urgency_trial_title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07370064",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Yake Biotechnology Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07370064",
      "https://clinicaltrials.gov/study/NCT07252336",
      "https://clinicaltrials.gov/study/NCT07144020",
      "https://clinicaltrials.gov/study/NCT05827835",
      "https://clinicaltrials.gov/study/NCT06836505",
      "https://clinicaltrials.gov/study/NCT06793241",
      "https://clinicaltrials.gov/study/NCT06787560",
      "https://clinicaltrials.gov/study/NCT06785519"
    ],
    "score_details": {
      "trial_count": 31,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 30
  },
  {
    "account_name": "Shanghai Xiniao Biotech Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases | trial_collaborator: Universal Chimeric Antigen Receptor T-Cell \uff08UCAR T-cell\uff09 Therapy Targeting CD19/B Cell Maturation Antigen \uff08CD1 | trial_collaborator: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases",
    "best_fit_trial_title": "CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07315087",
    "best_urgency_trial_title": "CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07315087",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Shanghai Xiniao Biotech Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07315087",
      "https://clinicaltrials.gov/study/NCT06939166",
      "https://clinicaltrials.gov/study/NCT06941129",
      "https://clinicaltrials.gov/study/NCT07155369",
      "https://clinicaltrials.gov/study/NCT06920433",
      "https://clinicaltrials.gov/study/NCT06933563",
      "https://clinicaltrials.gov/study/NCT06920446"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 31
  },
  {
    "account_name": "Hebei Taihe Chunyu Biotechnology Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human  | trial_collaborator: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | trial_collaborator: Autologous Transplantation Combined With BCMA CAR-T in the Treatment of Young NDMM",
    "best_fit_trial_title": "Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07259070",
    "best_urgency_trial_title": "Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07259070",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Hebei Taihe Chunyu Biotechnology Co., Ltd",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07259070",
      "https://clinicaltrials.gov/study/NCT07249073",
      "https://clinicaltrials.gov/study/NCT07169500",
      "https://clinicaltrials.gov/study/NCT07117305",
      "https://clinicaltrials.gov/study/NCT07109323",
      "https://clinicaltrials.gov/study/NCT05618041",
      "https://clinicaltrials.gov/study/NCT05388695",
      "https://clinicaltrials.gov/study/NCT07008872"
    ],
    "score_details": {
      "trial_count": 12,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 32
  },
  {
    "account_name": "Genentech, Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20- | trial_collaborator: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lym | trial_collaborator: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MC",
    "best_fit_trial_title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05633615",
    "best_urgency_trial_title": "A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06984341",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Genentech, Inc.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06984341",
      "https://clinicaltrials.gov/study/NCT05633615",
      "https://clinicaltrials.gov/study/NCT06357676",
      "https://clinicaltrials.gov/study/NCT07008378",
      "https://clinicaltrials.gov/study/NCT05464329",
      "https://clinicaltrials.gov/study/NCT05260957",
      "https://clinicaltrials.gov/study/NCT05801939",
      "https://clinicaltrials.gov/study/NCT06252675"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 33
  },
  {
    "account_name": "Gracell Biotechnologies (Shanghai) Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma | trial_collaborator: GC012F Injection in Refractory Idiopathic Inflammatory Myopathy | trial_candidate: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_title": "Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07250269",
    "best_urgency_trial_title": "A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06235229",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Gracell Biotechnologies (Shanghai) Co., Ltd.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06235229",
      "https://clinicaltrials.gov/study/NCT07086404",
      "https://clinicaltrials.gov/study/NCT06530849",
      "https://clinicaltrials.gov/study/NCT07250269",
      "https://clinicaltrials.gov/study/NCT07249879",
      "https://clinicaltrials.gov/study/NCT07058298",
      "https://clinicaltrials.gov/study/NCT07072884",
      "https://clinicaltrials.gov/study/NCT06880354"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 34
  },
  {
    "account_name": "A2 Biotherapeutics Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So | trial_candidate: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | trial_candidate: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S",
    "best_fit_trial_title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06051695",
    "best_urgency_trial_title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06051695",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "A2 Biotherapeutics Inc.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06051695",
      "https://clinicaltrials.gov/study/NCT04981119",
      "https://clinicaltrials.gov/study/NCT06682793",
      "https://clinicaltrials.gov/study/NCT05736731"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 35
  },
  {
    "account_name": "Poseida Therapeutics, Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | trial_candidate: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | trial_candidate: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies",
    "best_fit_trial_title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05239143",
    "best_urgency_trial_title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05239143",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Poseida Therapeutics, Inc.",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05239143",
      "https://clinicaltrials.gov/study/NCT04960579",
      "https://clinicaltrials.gov/study/NCT06014762",
      "https://clinicaltrials.gov/study/NCT03741127"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 36
  },
  {
    "account_name": "Cabaletta Bio",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia  | trial_candidate: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody  | trial_candidate: RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Activ",
    "best_fit_trial_title": "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04422912",
    "best_urgency_trial_title": "RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06359041",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Cabaletta Bio",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06359041",
      "https://clinicaltrials.gov/study/NCT04422912",
      "https://clinicaltrials.gov/study/NCT06121297",
      "https://clinicaltrials.gov/study/NCT07006805",
      "https://clinicaltrials.gov/study/NCT06154252",
      "https://clinicaltrials.gov/study/NCT06328777"
    ],
    "score_details": {
      "trial_count": 6,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 37
  },
  {
    "account_name": "Takeda",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myel | trial_collaborator: IVIG for Infection Prevention After CAR-T-Cell Therapy",
    "best_fit_trial_title": "IVIG for Infection Prevention After CAR-T-Cell Therapy",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05952804",
    "best_urgency_trial_title": "A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05748197",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Takeda",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05748197",
      "https://clinicaltrials.gov/study/NCT06980480",
      "https://clinicaltrials.gov/study/NCT05952804",
      "https://clinicaltrials.gov/study/NCT03263572",
      "https://clinicaltrials.gov/study/NCT04464200",
      "https://clinicaltrials.gov/study/NCT05020015",
      "https://clinicaltrials.gov/study/NCT05757700"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 38
  },
  {
    "account_name": "Cartesian Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Descartes-08 in Autoantibody Myositis | trial_candidate: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia G | trial_candidate: Descartes-08 for Patients With Systemic Lupus Erythematosus",
    "best_fit_trial_title": "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06799247",
    "best_urgency_trial_title": "Descartes-08 in Autoantibody Myositis",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07391605",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Cartesian Therapeutics",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07391605",
      "https://clinicaltrials.gov/study/NCT06799247",
      "https://clinicaltrials.gov/study/NCT06038474",
      "https://clinicaltrials.gov/study/NCT04146051"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 39
  },
  {
    "account_name": "Merck Sharp & Dohme LLC",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.1,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive an | trial_candidate: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or  | trial_collaborator: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukem",
    "best_fit_trial_title": "Pembro Plus CAR T-cell Therapy in R/R in PMBCL",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05934448",
    "best_urgency_trial_title": "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05458297",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Merck Sharp & Dohme LLC",
    "total_score": 20.1,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05458297",
      "https://clinicaltrials.gov/study/NCT06395103",
      "https://clinicaltrials.gov/study/NCT07194980",
      "https://clinicaltrials.gov/study/NCT07227597",
      "https://clinicaltrials.gov/study/NCT04201873",
      "https://clinicaltrials.gov/study/NCT03272334",
      "https://clinicaltrials.gov/study/NCT05934448",
      "https://clinicaltrials.gov/study/NCT04920617"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0
    },
    "rank": 40
  }
]